HealthTree Cure Hub is an online patient portal that invites patients to contribute to research.
There are over 11,000 registered patients in HealthTree Cure Hub and many have willingly helped contribute their myeloma story (anonymously) to speed academic research.
The HealthTree Research articles are findings from these online surveys, from data inside the database, and from larger studies. Some of the surveys and studies have been performed to support specific myeloma investigator's work. Others have been performed internally at HealthTree.
Myeloma investigators have called HealthTree Cure Hub a "hypotheses generation tool."
We are intensely grateful for patients who have contributed to this significant and important research and look forward to publishing many more results.
Dr. Omar Nadeem presented about immunotherapy for multiple myeloma patients at the Boston Myeloma Round Table and shared how research continues to accelerate.
Learn about the product NXC-201, a CAR-T that overcomes neurotoxicities, treats amyloidosis, and is potentially the first to be outpatient.
HealthTree Researchers discover myeloma patients' perspective on participating in clinical trials.
HealthTree performed a study to learn about the top concerns of newly diagnosed myeloma patients.
HealthTree Foundation and Adaptive joined forces to understand the awareness, knowledge, and perceptions of MRD testing among patients with multiple myeloma.
How do you make treatment decisions at myeloma relapse? Share your experience in our decision-making survey.
HealthTree developed a study that looked at how the number of medications used to treat myeloma affected the genetic risk of patients.
A HealthTree Research study shows adding another drug to a myeloma regimen did not increase the presence or severity of side effects.
HealthTree Foundation presents poster abstracts at the 64th ASH Annual meeting.